# A Study of Enasidenib in People With T-Cell Lymphoma

> **NCT06756308** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- T-cell Lymphoma

## Interventions

- **DRUG:** Enasidenib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06756308
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756308, "A Study of Enasidenib in People With T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06756308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*